Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 150

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 10
Chunk 150
---
 requirements of the Securities Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures Title Date     /s/ Alexander Tokman Acting Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) March 31, 2025Alexander Tokman         /s/ Richard Jacroux Chief Financial Officer (Principal Financial and Accounting Officer) March 31, 2025Richard Jacroux         /s/ Louis J. Basenese Director March 31 2025Louis J. Basenese         /s/ Anthony DiGiandomenico Director March 31, 2025Anthony DiGiandomenico         /s/ Michael Harsh Director March 31, 2025Michael Harsh    

 68